Recent News

The hospital’s comprehensive Nuclear Medicine Department, integrated with Burjeel Cancer Institute, offers advanced molecular imaging and expands access to targeted radionuclide therapies 

Sharjah, UAE, September 7, 2026: Burjeel Specialty Hospital, part of Burjeel Holdings, has launched the first PET/CT service in the Emirate of Sharjah, strengthening access to advanced cancer diagnostics and precision treatment closer to patients and families. 

The new service is part of the hospital’s comprehensive Nuclear Medicine Department and is fully integrated with Burjeel Cancer Institute (BCI), the fastest-growing cancer care network in the UAE. The integration connects molecular imaging with multidisciplinary oncology expertise across diagnosis, staging, treatment planning, and follow-up. 

The service was inaugurated in the presence His Excellency Sheikh Faisal bin Khalid bin Sultan Al Qasimi; Dr. Ahmad Tahlak, General Director, Tarahum Charity Foundation; Mohammad Al Mulla, Deputy Director-General, Tarahum Charity Foundation; Dr. Shamsheer Vayalil, Chairman and CEO, Burjeel Holdings; Mr. Abdul Wahab Al Halabi, Non-Executive Director, Burjeel Holdings; Mrs. Aisha Al Mulla, Director of the Friends of Cancer Patients Society. 

Advanced Imaging Closer to Patients 

At the center of the department is the GE Discovery IQ PET/CT system, combining advanced PET detector technology with CT imaging and reconstruction capabilities. It supports cancer diagnosis and staging, treatment-response assessment, recurrence detection, and quantitative imaging. High-sensitivity detector technology enables faster scan acquisition, while lower-dose imaging supports diagnostic performance with reduced radiation exposure. Q-Clear reconstruction further enhances image quality and quantitative accuracy. 

For patients, this means access to advanced molecular imaging services without the need to travel to another emirate. Faster scan times can help reduce the time spent undergoing imaging, while the integrated care model allows results to be reviewed by the wider oncology team, supporting timely and coordinated treatment decisions. The facility operates in line with FANR requirements and internationally recognized radiation safety standards, with patient safety and comfort remaining a key priority. 

“With this capability now available in Sharjah, we can support timely diagnosis, accurate staging and treatment-response assessment while keeping patient safety and comfort at the center of care,” said Dr. Firuz Ibrahim, Head of Department, Nuclear Medicine, Burjeel Specialty Hospital, Sharjah. 

The department offers PET/CT imaging using a broad range of advanced radiotracers. These include 18F FDG PET/CT for staging and treatment-response assessment across many cancers; PSMA PET/CT for prostate cancer; DOTA-peptide PET/CT for neuroendocrine tumors; and specialized tracers supporting evaluation of breast and brain cancers, sarcomas, pancreatic and gastric cancers, parathyroid adenoma, and cognitive impairment. 

Beyond diagnostic imaging, the Sharjah team will collaborate with the BCI Nuclear Medicine team in Abu Dhabi to provide access to targeted radionuclide therapies. These include radioactive iodine therapy for thyroid cancer, peptide receptor radionuclide therapy for neuroendocrine tumors, Lutetium-177 PSMA therapy for advanced prostate cancer, and selective internal radiation therapy for liver cancer and liver metastases. 

“PET/CT is an important tool throughout the cancer journey, from diagnosis and staging to treatment planning, response assessment, and detecting recurrence. Bringing this capability to Sharjah allows us to combine advanced molecular imaging with multidisciplinary cancer expertise so that each patient’s imaging can directly inform a personalized treatment plan,” said Prof. Dr. Humaid Al Shamsi, Chief Executive Officer of Burjeel Cancer Institute. 

The Nuclear Medicine team works closely with BCI specialists across oncology disciplines, creating a seamless pathway from imaging to treatment planning. Diagnostic and therapeutic services are guided by NCCN clinical guidelines and SNMMI/EANM imaging standards, supporting evidence-based, internationally benchmarked care. 

Three-day congress brings together global experts to advance diagnosis, treatment, research, and access to care for rare diseases 

Abu Dhabi, 3 September 2026: The Fifth MENA Congress for Rare Diseases 2026 has opened in Abu Dhabi, bringing together more than 1,500 participants and over 140 speakers specializing in genetic and rare diseases for three days of scientific exchange, collaboration, and discussion on the future of rare disease care and research. The congress is organized in partnership with Burjeel Medical City, Burjeel Cancer Institute, and the Genetics and Rare Disease Center. 

Held with the support and participation of the Department of Health – Abu Dhabi (DoH), the congress opened in the presence of Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, and Dr. Mujtaba Ali Khan, CEO of Burjeel Medical City. The event also welcomes 40 international experts from more than 20 countries to discuss the latest developments in the diagnosis, treatment, and research of rare diseases.  

Featuring more than 30 scientific sessions, this year’s congress expands the conversation beyond clinical advances to areas including the health economics of rare diseases, insurance coverage, and medical education. Discussions also cover emerging treatments such as enzyme replacement therapy, advances in diagnostic approaches, and the growing role of scientific research, innovation, and artificial intelligence in supporting the diagnosis and management of genetic and rare diseases. 

The congress is being held alongside the Third MENA Summit for Genetic Counselors, the Fourth MENA Summit for Duchenne Muscular Dystrophy, the Fourth MENA Summit for Angelman Syndrome, and the Fourth MENA Summit for Huntington’s Disease. 

The scientific program highlights advanced therapeutic approaches and technologies, including gene therapy for hemoglobinopathies, hemophilia, Duchenne muscular dystrophy, and spinal muscular atrophy, as well as emerging gene-editing approaches such as CRISPR-Cas9. 

Sessions also explore clinical trials and the development of innovative medicines in the MENA, genomics and multi-omics, and strategies to improve access to advanced therapies. Together, these discussions connect science, clinical practice, and innovation to help shape the next generation of rare disease care. 

Prof. Ayman El-Hattab, Director and Consultant Clinical Genetics at the Genetics and Rare Disease Center, Burjeel Medical City, and President of the Congress, said: “This congress provides a unique platform for specialists and stakeholders in rare diseases to come together, exchange knowledge and expertise, advance research, and identify new opportunities for collaboration. Our goal is to improve care and quality of life for people living with rare diseases in the region and beyond. We are proud to host the congress in Abu Dhabi for the fourth consecutive year, reflecting the capital’s growing role in bringing together the global healthcare and scientific community.” 

Research from Around the World 

The scientific program also features peer-reviewed research abstracts submitted by researchers from around the world. Three winning abstracts, submitted by researchers from Brazil, the United Kingdom, and France, will be recognized and presented during the congress’s scientific sessions. 

Prof. Khaled Musallam, Chairman of the Scientific Committee of the Congress, and Group Chief Research Officer at Burjeel Holdings, said: “The MENA faces a significant burden of rare diseases, and addressing gaps in diagnosis, treatment, and access to care requires collaboration across healthcare, research, industry, and patient communities. Through science, innovation, and stronger partnerships, we can accelerate progress and improve outcomes for people living with rare diseases across the region and beyond.” 

Outstanding Achievement in Rare Diseases Awards 

On the sidelines of the congress, the Awards for Outstanding Achievement in Rare Diseases recognized individuals and organizations that have made significant contributions to advancing the rare disease field. 

In the Clinician category, awards were presented to Dr. Arif Khan, Consultant Pediatric Neurology and Director of the Gene Therapy Program at Fakeeh University Hospital, and Dr. Cristina Skrypnyk, Consultant Medical Genetics, Genetics and Inherited Disorders Department, Al Jawhara Center for Molecular Medicine, Bahrain. 

Dr. Afsheen Raza, Associate Professor and Director of the Abu Dhabi University Cancer Research Institute, received the award in the Researcher category, while Prof. Mahir Al-Hilali, Senior Corporate Director of Laboratory Services at Mediclinic Middle East, was recognized in the Leader category. 

In the Organization category, the award was presented to Chiesi Ltd, a global biopharmaceutical company focused on developing innovative treatments, including therapies for rare diseases. CENTOGENE GmbH, a global diagnostics company headquartered in Germany that supports the diagnosis of patients with rare and genetic diseases, was also recognize

A group of 30 doctors, nurses, clinicians, healthcare leaders, and administrative staff shared stories of leadership, evolving opportunities, and aspirations during the unique Emirati Women’s Day Leadership Journey from Abu Dhabi to Fujairah. 

Abu Dhabi, 27 August 2026: Three generations of Emirati women working across healthcare came aboard Etihad Rail for a unique journey celebrating their achievements, leadership, and contributions to the UAE ahead of Emirati Women’s Day. 

Conceptualized and organized by Burjeel Holdings in collaboration with Etihad Rail, the Emirati Women’s Day Leadership Journey brought together 30 Emirati women for a special journey from Abu Dhabi to Fujairah and back. The participants included senior physicians, doctors, nurses, clinicians, healthcare leaders, and professionals from administrative and support functions, representing different generations and stages of their careers. 

Joining the women on the journey was H.E. Dr. Farida Al Ali, Assistant Undersecretary for National Talent Empowerment at the Ministry of Human Resources and Emiratisation (MoHRE). She shared insights from her leadership journey, highlighting resilience, career development, national contribution, and the growing role of Emirati women in shaping the future of the UAE’s workforce, healthcare sector, and society. 

Three Generations, One Healthcare Journey 

As the train traveled across the UAE, the journey became a setting for conversations about how the professional lives of Emirati women have evolved over the past several decades alongside the development of the country. Senior professionals, mid-career leaders, and younger professionals sat together discussing the evolution of the UAE’s healthcare sector. Women who entered healthcare when career pathways were still expanding exchanged experiences with established leaders shaping healthcare today and younger professionals preparing to take the sector into its next chapter. 

“Healthcare is built by people with very different skills, but with one shared purpose. On this journey, we brought together Emirati doctors, nurses, clinicians, leaders, and colleagues from administrative functions whose careers span different generations. Their stories show how far opportunities for Emirati women have progressed and, more importantly, how every generation is helping create the next set of opportunities. Seeing these conversations take place so naturally across generations was one of the most meaningful aspects of the journey,” said Dr. Tahani Al Qadiri, Associate Vice President - Burjeel Training Academy. 

The program featured leadership conversations, intergenerational discussions, networking, and reflections on resilience, career development, national contribution, and the future role of Emirati women in healthcare and society. 

“When we began our careers, Emirati women were rarely seen in many healthcare specialties. Today, it is inspiring to see the next generation stepping forward with confidence and ambition,” said Dr. Aysha Almahri, CEO - Al Ain Region, Burjeel Holdings. 

Sara Alkatheeri, Nutritionist at Burjeel Medical City (BMC), reflected on how the determination and achievements of the Emirati women who came before her paved the way for the next generation. 

“Today, we have the confidence to dream bigger because the women before us broke barriers and proved what was possible. Their legacy motivates us to keep raising the bar and contribute meaningfully to the future of healthcare in the UAE,” she said.  

The conversations also highlighted the often less-visible roles that keep healthcare systems moving. Alongside doctors and nurses, Emirati women working across administration, operations, patient services, and other functions shared how their work contributes to the delivery of care and the growth of the sector. 

A Journey Reflecting the UAE’s Progress 

The choice of Etihad Rail as the setting added a wider symbolism to the celebration. The journey reflected the broader story of a country that has continuously invested in connecting people, creating opportunities, and building for the future. 

The setting allowed participants to look beyond individual professional milestones and consider how their own journeys have been shaped by the UAE’s development. For each generation, it was an opportunity to reflect on the nation’s changes. 

The Emirati Women’s Day Leadership Journey also created informal opportunities for mentoring and networking, with women from different disciplines and career stages exchanging experiences throughout the journey. As the train returned to Abu Dhabi, one theme echoed across generations: progress is built from one generation to the next. While their experiences differed, each generation spoke of opening doors, creating opportunities, and ensuring those who follow can go further.

More than 1,000 healthcare professionals from 35 nationalities united for 250-sqm installation in Abu Dhabi. 

Abu Dhabi, 22 August 2026: More than 1,000 healthcare professionals from 35 nationalities have come together at Burjeel Medical City (BMC) in Abu Dhabi to create a giant Onam floral carpet (Pookalam) celebrating the UAE’s resilience, unity and continued progress under the leadership of President His Highness Sheikh Mohamed bin Zayed Al Nahyan. 

Spanning 250 sqm, the traditional floral carpet took almost 20 hours to create and features a prominent portrait of H.H. Sheikh Mohamed. It carries the message “The UAE is strong and resilient and emerging stronger,” inspired by words of reassurance from His Highness that offered confidence and hope to the community and became the central thought behind this year’s design. 

The Pookalam interprets resilience through the UAE’s journey from heritage to the future. A visual transition from a traditional camel ride to the Etihad Rail symbolizes the country’s transformation and continued progress, reflecting how strong foundations, long-term vision and determination have enabled the UAE to keep moving forward. 

Other floral elements represent unity and care, highlighting the strength of people coming together, and the importance of healing, recovery, and compassion. The permanent sand pendulum at the center of BMC’s atrium takes on special significance this year as a symbol of time, continuity and forward movement. 

For the healthcare professionals involved, the installation brings together the spirit of Onam with the values they associate with life in the UAE. Onam celebrates renewal, hope, prosperity and togetherness, while this year’s Pookalam reflects how those same values resonate with the country’s ability to face challenges with confidence and emerge stronger. 

Ms. Ameera Al-Katheri, an Emirati national and Assistant Director of Nursing at BMC, said: “Resilience in the UAE comes from the confidence we have in our leadership and in each other. This Pookalam reflects our journey, from the values we inherited to the progress we continue to make together.” 

Dr. Mujtaba Ali Khan, CEO of BMC, said: “This year’s Pookalam is a tribute to the strength and resilience that define the UAE. Bringing together more than 1,000 healthcare professionals from 35 nationalities to create it also reflects the unity and shared sense of belonging that make this country special.” 

Doctors, nurses and other healthcare professionals worked together to complete the floral carpet, reflecting the multicultural character of the UAE’s healthcare workforce and the collaborative spirit behind the annual celebration. 

Dr. Malcolm Borg, a British national and Consultant in Emergency Medicine at BMC, said: “In healthcare, resilience is something we witness every day. It is the ability to recover, adapt, and continue with hope. That is why this year’s theme has a particularly meaningful connection with our work and with the spirit of Onam.” 

Every year, the giant floral carpet at BMC becomes a major attraction of the UAE’s community Onam celebrations, with each edition interpreting the festival through a different national theme connected to the country’s values, priorities and aspirations.

Launched simultaneously at Burjeel Hospital Abu Dhabi and Burjeel Medical City, the integrated framework connects emergency, critical care, and interfacility transfers into a single, coordinated model 

Abu Dhabi, August 11, 2026: Bringing the full strength of its healthcare network together around emergency and acute care patients, Burjeel Holdings has launched BEACON, the Burjeel Emergency and Acute Care Operational Network. Launched simultaneously at Burjeel Hospital Abu Dhabi and Burjeel Medical City, the integrated framework connects emergency, critical care, and interfacility transfers into a single, coordinated model across Abu Dhabi facilities. 

BEACON is designed to ensure that wherever patients first enter the Burjeel network, they can be rapidly connected to the right expertise and the most appropriate level of care. From the initial response and emergency assessment to specialist intervention, critical care, transfer, recovery, and follow-up, the model brings different elements of the patient journey together through shared clinical pathways and coordinated decision-making. 

The launch was marked at an event held at Burjeel Hospital Abu Dhabi, attended by Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings; Mr. Omran Al Khoori, Member of the Board of Directors at Burjeel Holdings; and senior medical professionals from across the Group. 

One Network, One Clinical Standard 

BEACON establishes a common framework for emergency and acute care. Rather than treating the Emergency Department as an isolated point of care, the model connects the patient with the wider capabilities of the network based on clinical need. This includes access to specialist and subspecialist teams, intensive care, diagnostics, inpatient services, and advanced treatment capabilities across the two hospitals. 

The framework is built around four key areas: acute care access, Emergency Department quality and value, integration between the Emergency Department and the wider hospital, and interfacility transfer and prehospital integration. It also strengthens subspecialty routing, standardized clinical protocols, and technology-enabled clinical decision support.   

“When a patient faces an emergency, the strength of our entire healthcare network should be available to them. BEACON brings our people, expertise, infrastructure, and capabilities together around the patient, enabling our teams to respond in a more coordinated and consistent way. Our focus is to connect every patient to the right expertise and level of care when it matters most, while maintaining the highest standards of quality, safety, and patient experience,” said Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings. 

Connecting Care Across the Patient Journey 

By bringing emergency, diagnostic, specialist, and inpatient teams together, BEACON helps reduce unnecessary delays and repeated assessments. Depending on the patient’s condition, emergency physicians can involve specialists in cardiology, neurology, oncology, maternal-fetal medicine, intensive care, surgery, pediatrics, and other disciplines from an early stage in the care process. 

Patients requiring capabilities available at another site can be transferred through coordinated clinical pathways, with the relevant teams involved in decision-making before and during the transfer. This helps patients reach the right specialist care within the Burjeel network more quickly and supports continuity between facilities. 

The model is designed to deliver clinical excellence through experienced teams working to shared standards of care across both hospitals, helping ensure safe, high-quality, and seamless care throughout the patient journey.  

“Emergency care does not begin or end at the doors of the Emergency Department. A patient may need prehospital support, rapid diagnostics, specialist intervention, critical care, or transfer to another facility, often within a very short period of time. BEACON gives our teams a common framework to coordinate these decisions and act as one clinical network. This helps us bring the appropriate expertise to the patient earlier and maintain a consistent standard throughout the care journey,” said Dr. Malcolm Borg, Consultant and Group Head, Emergency Medicine. 

BEACON supports both common emergencies and complex, time-sensitive conditions through standardized pathways across cardiac emergencies, stroke, sepsis, trauma, pediatrics, and acute oncology, while also enabling access to highly specialized and quaternary care across the network. 

Technology support will improve visibility of clinical capacity and specialist availability across participating facilities, helping teams make informed decisions about where patients should receive care. 

The framework also includes the progressive use of clinical decision support and predictive tools to help identify high-risk patients earlier, support acute care navigation, and monitor key quality indicators. Clinician oversight remains central to all technology-enabled decision-making. 

Following its launch at Burjeel Hospital Abu Dhabi and Burjeel Medical City, BEACON will progressively extend across Burjeel’s wider acute care network.  

greement to support integrated healthcare programs, preventive health initiatives, national policy development, and specialized services for priority groups 

Abu Dhabi: The Ministry of Family and Burjeel Holdings have signed a Memorandum of Strategic Partnership to advance family health and quality of life through coordinated, sustainable initiatives. The partnership supports the UAE’s vision of placing the family at the heart of development and social stability and coincides with the Year of the Family. 

The Memorandum was signed by Mr. Omran Al Khoori, Member of the Board of Directors and Chief Business Development Officer at Burjeel Holdings, and Ms. Marwa Al Marzooqi, Acting Assistant Undersecretary for Support Services, Ministry of Family, in the presence of H.E. Sana bint Mohammed Suhail, Minister of Family, and Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings. 

The agreement establishes a framework for integrated healthcare programs, preventive and holistic health initiatives, community awareness, and specialized support for senior citizens, People of Determination, mothers, children, youth, and those preparing for marriage. It will also draw on Burjeel Holdings’ medical and advisory expertise to support national policies related to marriage, fertility, family growth, and sustainability. 

Strengthening Family Health and Stability 

H.E. Sana bint Mohammed Suhail said the Ministry continues to expand partnerships with national institutions, recognizing family stability and quality of life as shared national responsibilities requiring aligned efforts and expertise. She noted that the collaboration will help connect innovative family policies with healthcare services across different stages of life. 

“Through this collaboration, we are focused on launching practical initiatives with sustainable impact across preventive health, mental health, maternal and child health, support for those preparing for marriage and fertility, and healthy aging programs. These efforts will contribute to more integrated services for priority groups, enhance families’ quality of life, and strengthen the family’s pivotal role in raising generations rooted in their values and national identity who contribute effectively to the UAE’s development journey, in line with the ‘We the UAE 2031’ vision,” H.E. Sana Suhail said. 

Dr. Shamsheer Vayalil said: “The health and wellbeing of families are central to building a cohesive, resilient, and prosperous society. We are proud to support the Ministry of Family’s efforts through integrated healthcare programs, preventive health initiatives, and specialized support for different stages of family life. By contributing our medical expertise and capabilities, we aim to support better outcomes for mothers and children, senior citizens, People of Determination, and other priority groups, while advancing the UAE’s vision for healthier families and a stronger, more sustainable society.” 

Integrated Programs and Community Initiatives 

Under the agreement, the two entities will develop preventive and therapeutic healthcare packages through the “Family Wellness” programs and provide healthcare services for Ministry of Family employees and their families. Specialized programs will promote families’ mental and physical wellbeing and support stability and quality of life. 

The partnership will introduce community initiatives for youth, families, and those preparing for marriage, while supporting national programs associated with the Year of the Family. Awareness campaigns, training, and educational workshops will promote reproductive health, mental health, and maternal and child health and encourage positive health behaviors. 

Joint initiatives will include a national model for healthy aging aligned with federal policies; specialized and integrated services for senior citizens and People of Determination; and the “Family Support” program to train and qualify caregivers according to accredited professional standards. The collaboration also covers first aid and emergency response programs and evidence-based technical recommendations to support fertility policies. 

The program will support clinical electives, faculty exchange, joint education, and collaborative research, with training facilitated by Burjeel Training Academy. 

Abu Dhabi, August 04, 2026: Burjeel Cancer Institute at Burjeel Medical City has signed a Memorandum of Understanding with Loyola University Chicago Stritch School of Medicine to advance medical education, clinical training, academic exchange, and collaborative research, with an initial focus on oncology. The agreement developed through exchange visits involving Burjeel Cancer Institute and Loyola University Chicago’s Cardinal Bernardin Cancer Center, during which representatives explored opportunities across cancer education, clinical training, research, and patient care. 

The clinical training program under the agreement will be coordinated and facilitated by Burjeel Training Academy, the medical education and professional development arm of Burjeel Holdings. The agreement represents the Academy’s first academic collaboration with a medical school in the United States. 

Under the MoU, medical students from Stritch School of Medicine will be able to undertake supervised clinical electives and training experiences across Burjeel Holdings’ hospitals and specialty centers in the UAE. 

New Opportunities in Clinical Education and Research 
 
Students will gain exposure to a range of medical and surgical specialties while learning within a healthcare system serving a diverse patient population. The structure and duration of the electives will be determined jointly by the institutions and will be subject to applicable academic and regulatory requirements. 

“This agreement strengthens the academic relationship established between Burjeel Cancer Institute and Cardinal Bernardin Cancer Center. It creates opportunities to advance oncology education and research while enabling students and faculty from both institutions to benefit from shared clinical knowledge and experience,” said Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute. 

In addition to student electives, the agreement provides a framework for faculty exchange, joint educational programs, collaborative research, and the development of new clinical learning opportunities. 

“As Burjeel Training Academy’s first collaboration with a US medical school, this partnership reflects confidence in the clinical education and training offered across Burjeel Holdings. We look forward to delivering structured learning opportunities that prepare future physicians to work in diverse and interconnected healthcare environments,” said Dr. Tahani Al Qadiri, Associate Vice President of Burjeel Training Academy. 

Burjeel Training Academy coordinates undergraduate and postgraduate clinical education and professional development programs across Burjeel Holdings. Its programs include observerships, clinical clerkships, medical and dental internships, residency and fellowship training, return-to-practice programs, and continuing medical education and professional development. 

Dr. Theresa Nguyen, Director of the Center for Community and Global Health, Professor of Emergency Medicine, Stritch School of Medicine, said, “The agreement will provide our students with an opportunity to learn in a different healthcare environment and engage with clinicians serving patients from varied cultural and clinical backgrounds. We also look forward to exploring opportunities for faculty collaboration, education, and research with colleagues across Burjeel Cancer Institute and the wider Burjeel network.” 

Founded in 1909, Loyola University Chicago Stritch School of Medicine provides undergraduate, graduate, and continuing medical education, as well as biomedical sciences education and research. Its Health Sciences Campus includes the Cardinal Bernardin Cancer Center, which integrates cancer research, education, and patient care. 

Burjeel Cancer Institute at Burjeel Medical City brings together multidisciplinary expertise across medical, surgical, and radiation oncology, hematology, bone marrow transplantation, precision medicine, and supportive care. 

The new center serves as a qualitative addition to Al Ain’s healthcare ecosystem, bringing a comprehensive suite of sports medicine subspecialties under one roof 

Al Ain, July 22, 2026: Burjeel Royal Hospital, Asharej, in collaboration with the Abu Dhabi Sports Council, has launched the Burjeel Sports Medicine Center, marking a major step forward in enhancing specialized healthcare services in line with the rapid growth of the Emirate’s sports sector. The opening ceremony was attended by Council representatives, dignitaries, and officials from government entities across Al Ain. The Center delivers an integrated model for injury prevention, diagnosis, treatment, and rehabilitation, with all services adhering to international best practices. 

Designed as a one-stop destination for sports healthcare, the Center brings together multidisciplinary expertise under one roof, spanning orthopedics, physiotherapy, advanced rehabilitation, diagnostic imaging, injury prevention, and athletic performance optimization. This holistic framework ensures a seamless continuum of care, from accurate initial diagnosis to a safe, effective return to play and daily routine. 

The facility caters to a broad spectrum of patients, including elite professional athletes, amateur sports enthusiasts, fitness advocates, pediatric patients, and individuals suffering from musculoskeletal conditions. Powered by a collaborative team of specialists, the Center features cutting-edge medical imaging, such as high-precision MRI, X-ray, and diagnostic ultrasound, alongside state-of-the-art rehabilitation suites and minimally invasive treatment options engineered to accelerate recovery and drive optimal clinical outcomes. 

The opening aligns with Burjeel’s strategic vision to scale sports medicine access across Al Ain, with upcoming expansion plans targeting Burjeel Royal Hospital, Town Center, Burjeel Medical Center, Barari Mall, and Burjeel Day Surgery Center, Al Dhahir. By decentralizing these high-tier services, Burjeel aims to bring specialized care closer to the community while reducing the need for patients to travel elsewhere for treatment. Furthermore, the Center will actively foster partnerships with local sports clubs, educational institutions, and corporate entities to promote injury prevention and athletic wellness across the region. 

Dr. Aysha Al Mahri, CEO, Al Ain Region, Burjeel Holdings said, “The launch of the Burjeel Sports Medicine Center represents a strategic milestone in our ongoing effort to elevate specialized healthcare standards in Al Ain. Developed in response to the surging demand for sports healthcare, this facility fuses elite multidisciplinary expertise with advanced diagnostic and therapeutic technologies. Our goal is to provide end-to-end care, from prevention and intervention to recovery, empowering patients and athletes to return to their active lifestyles with maximum confidence and safety.” 

Dr. Ahmed Al Marzooqi, Medical Director, Burjeel Al Ain, added, “Our Center is engineered to serve as a flagship hub for sports medicine in Al Ain, offering a continuous, patient-centric treatment journey. We focus on delivering personalized care plans designed to speed up recovery, minimize the risk of re-injury, and enhance physical performance. In tandem with modern clinical care, we are deeply committed to community engagement, partnering with local sports clubs, schools, and organizations to drive awareness and nurture a healthier, more active society.” 

The establishment of the Burjeel Sports Medicine Center underscores Burjeel Holdings’ commitment to continuous investment in specialized medical care. By expanding access to advanced, evidence-based therapies, the Group supports the UAE’s broader vision to foster athletic excellence, elevate quality of life in communities, and solidify Al Ain’s position as a growing center for world-class healthcare. 

The collaboration will establish a specialized thoracic surgery program in Abu Dhabi, expanding regional access to advanced, multidisciplinary care for cancers of the lung, esophagus, mediastinum, and chest wall 

New York | Abu Dhabi, July 17, 2026: Burjeel Medical City (BMC), the flagship facility of Burjeel Holdings, has entered into a clinical and academic collaboration with New York-based Roswell Park Comprehensive Cancer Center, a US National Cancer Institute-designated Comprehensive Cancer Center, to establish a specialized thoracic surgery program in the UAE. 

The agreement was signed in New York by Dr. Candace S. Johnson, President and CEO of Roswell Park Comprehensive Cancer Center, and Dr. Mujtaba Ali Khan, CEO of Burjeel Medical City. The signing took place in the presence of Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings, and Dr. Sai Yendamuri, Senior Vice President, Chief Strategy Officer and Chair of Thoracic Surgery at Roswell Park. 

The collaboration combines Roswell Park’s clinical protocols, multidisciplinary expertise, and academic capabilities with BMC’s advanced infrastructure, oncology services, and network. BMC will establish a dedicated thoracic surgery service for cancers affecting the lungs, esophagus, mediastinum, and chest wall. 

The program will offer robot-assisted, video-assisted thoracoscopic (VATS), and conventional open procedures based on clinical needs. By making specialized thoracic cancer surgery available in Abu Dhabi, the collaborators aim to reduce the need for patients from the UAE and wider MENA region to travel overseas. 

Expanding Access to Specialized Cancer Care 

The program will be integrated into the multidisciplinary care pathway of Burjeel Cancer Institute (BCI), bringing together thoracic surgery, medical oncology, radiation oncology, pulmonology, pathology, and radiology. Patients will receive coordinated care from diagnosis through surgery, recovery, and follow-up. 

Thoracic tumor board meetings will allow BMC physicians to review complex cases with Roswell Park specialists. The collaboration will also provide access to Roswell Park faculty for selected reviews and second opinions. Clinical pathways will align with international standards, including National Comprehensive Cancer Network guidelines. 

Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings, said: “This collaboration creates a sustainable pathway for patients in the UAE and across the region to access highly specialized thoracic cancer care closer to home. By combining Roswell Park’s expertise with BMC’s capabilities and regional reach, we aim to strengthen outcomes, build local expertise, and reduce the burden of traveling overseas for complex treatment.” 

Building a Long-Term Academic Relationship 

The lead thoracic surgeon will hold an academic designation with Roswell Park. The institutions will also collaborate on clinical protocol development, scientific programs, educational activities, faculty engagement, clinician exchanges, and professional development. 

Dr. Candace S. Johnson, President and CEO of Roswell Park Comprehensive Cancer Center, said: “Roswell Park has a long-standing commitment to advancing cancer care through collaboration, research, and education.”  

Dr. Sai Yendamuri, Senior Vice President, Chief Strategy Officer and Chair of Thoracic Surgery at Roswell Park Comprehensive Cancer Center, said: “By working with Burjeel Medical City, we can extend specialized thoracic cancer care expertise, support multidisciplinary decision-making, and help build a world-class program serving patients across the UAE and region.” 

Founded in 1898 in Buffalo, New York, Roswell Park was the first institution established exclusively for cancer research and treatment and is a member of the National Comprehensive Cancer Network. 

The program will complement Burjeel Cancer Institute’s multidisciplinary oncology services, including medical oncology, surgical oncology, radiation oncology, advanced imaging, precision diagnostics, and supportive care. 

The patient, treated at Burjeel Hospital, Abu Dhabi, suffered from Adult-Onset Still’s Disease (AOSD), a rare autoimmune condition affecting approximately 1–4 people per million worldwide 

Abu Dhabi: The 34-year-old patient residing in Abu Dhabi had always enjoyed robust health. So, when persistent high-grade fever plagued him for more than two weeks, it was deeply unsettling for him. Despite multiple hospital visits and extensive routine testing, including blood cultures and standard infection screens, the cause of his illness remained unknown, intensifying worries as his condition continued to worsen. With fever, disabling joint pain, extreme fatigue, and evidence of intense inflammation, and liver involvement, his condition started to raise concern as he began to show signs of a potentially life-threatening illness. 

Although he looked stable, the severity and persistence of his symptoms were alarming, prompting the medical team at Burjeel Hospital, Abu Dhabi, to intervene urgently. An in-depth investigation revealed that he was affected by Adult-Onset Still’s Disease (AOSD), a rare autoimmune condition affecting approximately 1–4 people per million worldwide. 

A Difficult-to-Diagnose Disorder  

Dr. Niyas Khalid, Specialist, Internal Medicine, says AOSD is extremely difficult to diagnose because of its rarity and resemblance to other infections. “It mimics many life-threatening diseases such as severe infections, autoimmune disorders, liver disease, and even cancer. It’s often under-recognized, particularly in regions where fever is commonly attributed to infectious causes,” says Dr. Niyas, who treated the patient along with Dr. Abdul Hakeem Muhammed, Specialist, Internal Medicine.  

At the hospital, the patient underwent a series of tests to rule out other possibilities. A major challenge was his body not having rashes, a feature often described in textbooks, but frequently absent or difficult to detect in individuals with darker complexion, adds the doctor.  

In his case, what stood out was the unique combination of prolonged fever, severe inflammation, liver involvement, and extremely high ferritin levels. In addition, all infectious and autoimmune tests had returned negative. “The extraordinarily elevated ferritin, a marker of inflammation, acted as a critical diagnostic signal. When these features came together, along with high-grade fever spiking every day at regular intervals, AOSD became the most plausible explanation, although it is extremely rare,” says Dr. Niyas. 

Fatal if Not Diagnosed in Time 

When affected by AOSD, the patient’s immune system becomes overactive and attacks itself, causing widespread inflammation. If not diagnosed and treated at the right time, the disease can progress to severe complications such as organ damage, chronic inflammatory arthritis, liver failure, or a potentially fatal immune storm known as macrophage activation syndrome. In this case, early intervention was life-altering and, potentially, life-saving. 

“During those days, I shivered from fever and struggled to get up from bed, lift my hands, and move my body. There was no appetite because of throat pain. Despite taking medicine, my fever recurred, draining me emotionally. I prayed to God to give my routine life back,” recalls the patient. 

Rapid Return to Normalcy  

Once AOSD was suspected, the medical team initiated high-dose corticosteroid therapy, the cornerstone treatment for this condition. After the initial high doses, the steroid was tapered carefully over several weeks to suppress the immune reaction while allowing safe recovery. “Within 24 hours, the fever subsided. Within 48 hours, the patient felt significantly better, with improvement in joint pain and energy levels. Laboratory markers improved in parallel,” explains Dr. Niyas. 

“I am so happy that I can move my body without support for the first time after a while. Everyone in the hospital gave me hope whenever I doubted, got frustrated, and questioned myself,” says the patient. 

Although he has recovered remarkably well, ongoing follow-up is essential as AOSD can recur in some patients. He will continue regular follow-up with internal medicine and rheumatology to monitor any signs of relapse and ensure long-term stability. 

Abu Dhabi, UAE, xx June 2026 - Abu Dhabi has marked a global milestone achievement by becoming the first in the world where Camizestrant, a next-generation therapy for advanced breast cancer, has been administered to a patient in a clinical care setting. The treatment is designed to support earlier, more targeted intervention for patients whose cancer has developed resistance to conventional hormone therapy. The achievement reflects Abu Dhabi’s position as a leading destination for best-in-class care, where advanced diagnostics and timely access to specialised treatments are supporting more personalised care. 

Under the supervision of the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, Burjeel Cancer Institute has administered this novel precision therapy to a woman in her forties diagnosed with advanced breast cancer. The patient was found to have an ESR1 gene mutation, which may cause the cancer to become resistant to conventional endocrine treatment and allow the disease to progress. 

The mutation was detected through circulating tumour DNA (ctDNA) monitoring, a blood-based approach that can identify molecular changes linked to treatment resistance before disease progression becomes visible on scans or through clinical symptoms.  

Camizestrant offers a more targeted treatment option for patients whose cancer has developed ESR1 gene mutation. By providing a more precise and personalised treatment option before clear signs of disease progression appear, it may help to control the cancer for longer, delay further progression and preserve patients’ quality of life. 

Commenting on the achievement, H.E Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH) said: The future of healthcare is not defined by treating disease, but by how early we can identify change and intervene before a patient’s condition progresses. Enabling the first global administration of Camizestrant in a clinical setting reflects Abu Dhabi’s vision of building one of the world’s most intelligent and advanced healthcare systems, founded on prevention, early detection, and timely intervention. By accelerating responsible access to advanced therapies with tangible impact at the right time, Abu is enabling precision medicine and more personalised care, improving patient outcomes and reinforcing its position as a leading global destination for healthcare”. 

Prof. Humaid Bin Harmal Al Shamsi, Chief Executive Officer of Burjeel Cancer Institute, added: "We are proud that Burjeel Cancer Institute has become the first centre in the world to treat a patient with this innovative therapy. This milestone reflects Burjeel Cancer Institute’s vision of integrating advanced molecular diagnostics, artificial intelligence, and sophisticated analytical technologies into the patient care pathway, enabling more personalised and precise treatment decisions tailored to the biological characteristics of each individual case." 

He added: "This achievement is not simply about introducing a new drug; it represents the adoption of a comprehensive precision oncology model built on continuous molecular monitoring. Through ctDNA testing, we are now able to detect endocrine therapy resistance at a very early stage and intervene before any radiological or clinical signs of disease progression emerge, giving patients a greater opportunity to control their disease while preserving their quality of life." 

The treatment approach is supported by findings from the global SERENA-6 clinical trial. The study showed that switching patients with an ESR1 mutation detected through ctDNA monitoring to Camizestrant reduced the risk of disease progression or death by 56% compared with continuing conventional endocrine therapy. 

SERENA-6 is the first global registrational trial to use serial ctDNA monitoring to guide a treatment change before radiological or clinical disease progression becomes evident, representing a significant shift in the management of advanced breast cancer. 

Burjeel Cancer Institute continues to strengthen its position as one of the region’s leading centres for oncology and precision medicine by providing advanced molecular diagnostics, multidisciplinary tumour boards, access to innovative therapies and clinical trials, and continued investment in advanced technologies and scientific research. 

This latest global milestone reinforces the Burjeel Cancer Institute’s commitment to providing advanced cancer treatments and scientific innovations to patients, while reflecting Abu Dhabi’s position as a leading destination for specialised care and precision oncology. 

• The clinic provides specialized care to support early diagnosis and effective treatment across workplaces 

Abu Dhabi, June 11, 2026: Lifecare Hospital - Musaffah, part of Burjeel Holdings, has launched a Seasonal Illness Clinic as part of its commitment to expanding specialized services, strengthening prevention, early detection and ensuring timely access to treatment. The clinic aims to support the health and wellbeing of workers and the wider community through integrated diagnostic and therapeutic services.  

The clinic inauguration was held in the presence of H.E. Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi; H.E. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi; Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings; and senior leaders of the Group. The clinic will provide comprehensive and affordable services, including medical assessment, treatment, preventive screening, consultations, patient education and ongoing support to all patients. 

“Musaffah is home to a large and diverse workforce that plays a vital role in the development of the UAE. Ensuring their health and safety is a shared responsibility. Through this clinic, we are bringing specialized infectious disease care, preventive screening, and health education closer to workers and the wider community. This is part of Burjeel Holdings’ commitment to accessible, responsive, and community-focused healthcare,” said Dr. Shamsheer. 

Located in one of Abu Dhabi’s key industrial areas, Lifecare Hospital, Musaffah, has long served as an important healthcare provider for Abu Dhabi’s industrial sector, supporting workers, employers, and surrounding communities with accessible medical services. Led by Dr. Rakesh Kumar Gupta, Consultant in Respiratory Medicine and Medical Director of Lifecare Hospital, Musaffah, the Seasonal Illness Clinic builds on the hospital’s extensive experience and integrated infrastructure, including dedicated isolation facilities when required.  

H.E. Dr. Faisal Al Ahbabi, Executive Director of Communicable Diseases Sector at Abu Dhabi Public Health Centre, said: “The inauguration of the Seasonal Illness Clinic reflects our ongoing efforts to provide specialized services that enhance prevention, early detection and timely intervention. This facility further safeguards the health and wellbeing of community members across the Emirate, reduces the spread of infectious diseases, and enhances the resilience of the healthcare system. This milestone aligns with Abu Dhabi’s vision to build a more proactive, prevention-led ecosystem that is human-centered and enables access to high-quality care for all.”  

The clinic focuses on the diagnosis and management of a range of common conditions, including respiratory and gastrointestinal infections, as well as skin and soft tissue infections, in addition to cases requiring specialized follow-up.  

 Leveraging Burjeel Holdings’ integrated healthcare network, the clinic will enable coordinated access to advanced diagnostic care and comprehensive clinical expertise across the Group’s healthcare network. 

Additionally, the clinic will also work closely with employers, labor accommodations and community groups to support awareness programs, screening campaigns and counseling services. By identifying infections early and ensuring appropriate treatment, the clinic aims to reduce transmission in workplaces and residential settings. 

“Our clinic is designed to extensive structured care, from screening and diagnosis to treatment, counseling, and prevention. We will also focus heavily on educating patients and empowering them to understand how to protect themselves, their families, and their colleagues.” Dr. Rakesh said. 

With the launch of the clinic, Lifecare Hospital Musaffah aims to further strengthen public health support in Abu Dhabi by combining clinical expertise, preventive healthcare, and community outreach in one dedicated service.